Who is sponsoring NCT05692661?

NCT05692661 is sponsored by Shanghai Proton and Heavy Ion Center.

What drugs are being tested in NCT05692661?

Interventions in NCT05692661: proton plus carbon ion radiotherapy.

What condition does NCT05692661 study?

NCT05692661 studies Triple Negative Breast Cancer, HER2-positive Breast Cancer.

Is NCT05692661 still recruiting?

NCT05692661 is currently status unknown. Last updated 20 January 2023.

Last reviewed 2023-01-20 · How we verify

NCT05692661

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Status unknown Phase 1 Last updated 20 January 2023

What this trial tests

Phase 1 trial testing proton plus carbon ion radiotherapy in Triple Negative Breast Cancer in 24 participants. Status unknown.

Timeline

10 January 2023

Primary endpoint
10 October 2025

10 January 2026

Quick facts

Lead sponsor	Shanghai Proton and Heavy Ion Center
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	10 January 2023
Primary completion	10 October 2025
Estimated completion	10 January 2026
Sites	1 location across China

Drugs / interventions tested

proton plus carbon ion radiotherapy

Conditions studied

Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →

Sponsor

Shanghai Proton and Heavy Ion Center — full company profile →

Who can join

Adults 18 to 80, female only, with Triple Negative Breast Cancer or HER2-positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adjuvant radiotherapy is the standard treatment for early breast cancer after breast conserving surgery. Molecular subtypes was significantly associated with the risk of local recurrence of breast cancer. Nguyen et al found that the overall 5-year cumulative incidence of local recurrence was 0.8% for luminal A, 1.5% for luminal B, 8.4% for HER2 positive, and 7.1% for triple negative breast cancer after lumpectomy and radiotherapy. Her2 positive and triple negative breast cancers may be inherently radioresistant. Therefore, for HER2 positive and triple negative breast cancer with high local recurrence and radiation resistance, proton combined with carbon ion is proposed after breast conserving surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A future directions of renal cell carcinoma treatment: combination of immune checkpoint inhibition and carbon ion radiotherapy.
Zheng Z, Yang T, Li Y, Qu P, et al · · 2024 · cited 9× · PMID 39091498 · DOI 10.3389/fimmu.2024.1428584

Verify or expand the search:

Other recruiting trials for Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting

Other Shanghai Proton and Heavy Ion Center trials

Trials by the same sponsor.

NCT07135661 — Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy · NA · recruiting
NCT05613452 — Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT06677879 — A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. · Phase 2 · recruiting
NCT05878678 — Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position · Phase 2 · unknown
NCT05692674 — A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Br · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05692661 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Proton and Heavy Ion Center
Last refreshed: 20 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05692661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing